Semaglutide
★ 98 FDA approvedSemaglutide (Ozempic, Wegovy)
GLP-1 agonist — weight loss and glycemic control
Fat LossAbout
A GLP-1 receptor agonist, FDA-approved for type 2 diabetes and obesity. One of the most effective weight-loss medications available.
Mechanism
Mimics GLP-1, increases insulin, suppresses glucagon, slows gastric emptying, reduces appetite.
Dosage
beginner
- Amount
- 0.25 mg
- Frequency
- 1x per week for 4 weeks
- Route
- SubQ
- Duration
- Titration phase
standard
- Amount
- 0.5 mg → 1.0 mg → 1.7 mg
- Frequency
- 1x per week, increasing every 4 weeks
- Route
- SubQ
- Duration
- 16+ weeks
advanced
- Amount
- 2.4 mg (max dose)
- Frequency
- 1x per week
- Route
- SubQ
- Duration
- Long-term (12+ months)
Same day each week. Timing relative to meals matters little.
Not cycled — long-term use. Taper gradually if discontinuing.
Reconstitution & Storage
Store refrigerated after reconstitution, 30 days.
Dosing reference — units to draw
Concentration = peptide mass ÷ bacteriostatic water; units to draw = dose volume (mL) × 100 on a U-100 insulin syringe. Each vial size below is shown at 1 mL, with the units to draw for a typical 0.25–2.5 mg dose.
| Vial | BAC water | Concentration | Units to draw |
|---|---|---|---|
| 2 mg | 1 mL | 2 mg/mL | 12.5–125 units |
| 5 mg | 1 mL | 5 mg/mL | 5–50 units |
| 10 mg | 1 mL | 10 mg/mL | 2.5–25 units |
| 20 mg | 1 mL | 20 mg/mL | 1.5–12.5 units |
| 50 mg | 1 mL | 50 mg/mL | 0.5–5 units |
Prescription product: refrigerated. Compounded: 2-8°C, 30-56 days after reconstitution.
Benefits
- • 15-20% weight loss (STEP trials)
- • Improved glycemic control
- • Lowered HbA1c
- • Reduced cardiovascular risk (SELECT trial)
- • Reduces appetite and 'food noise'
Side effects
- • Nausea (common initially)
- • Diarrhea / constipation
- • Reflux
- • Fatigue
- • Rare: gallstones, pancreatitis
Contraindications
- • Medullary thyroid carcinoma (history)
- • MEN 2 syndrome
- • Pregnancy
- • History of pancreatitis
Gender notes
Men
Same dose, same efficacy.
Women
Same dose. Discontinue at least 2 months before pregnancy. May reduce oral contraceptive efficacy.
Research
- STEP 1: Semaglutide 2.4 mg for obesity ↗
Landmark RCT, 1961 participants. 14.9% weight loss at 68 weeks vs 2.4% placebo.
New England Journal of Medicine · 2021
- SELECT Trial: Cardiovascular outcomes ↗
20% reduction in MACE (cardiovascular events) in obese patients without diabetes.
New England Journal of Medicine · 2023
Stacks well with
Semaglutide FAQ
How do you reconstitute Semaglutide?
Add 1 mL of bacteriostatic water to a 2 mg vial of Semaglutide, which gives a concentration of 2 mg/mL. Inject the water slowly down the vial wall and swirl gently — never shake.
What is a typical Semaglutide dose?
A typical research dose of Semaglutide is 0.25–2.5 mg, 1x per week, increasing every 4 weeks. This is educational information, not medical advice.
How many units of Semaglutide do I draw?
From a 2 mg vial reconstituted with 1 mL of bacteriostatic water, draw 12.5–125 units on a U-100 insulin syringe for a 0.25–2.5 mg dose.
Track Semaglutide doses in the app
Built-in reconstitution calculator, dose log, and reminders. Free on Android.
Get on Google PlayEducational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.